Procaps Group SA (PROC): Price-to-Sales Ratio

Symbol and logo of brand Procaps Group (PROC)

Procaps Group S.A. (PROC) minimizes risks through a combination of proprietary brands and third-party orders. The company's market capitalization-to-revenue ratio visualizes market demand for the business, where 0.60 represents the latest level. Revenues are based on the production of softgels and CDMO services. Long-term B2B contracts in Latin America ensure a stable cash flow, supporting the enterprise's operational resilience.

PROC: Procaps Group SA Price-to-Revenue Ratio 07/04/2022 - 12/31/2024

Analytical breakdowns for Procaps Group SA (PROC)

- share price and consensus valuation forecast:
Price Performance Chart procapsgroup.com|PROC - Price Target Chart
- stock exchange capitalization data:
Market Valuation Procaps Group SA|PROC - Total Company Value
- balance sheet net asset value indicators:
Accounting Value of a Share Procaps|PROC - Company Book Value|Market-to-Book Ratio procapsgroup.com|PROC - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Procaps Group S.A.|PROC - Long-Term Debt to Capital|Short-Term Debt to Capital Procaps Group Corp|PROC - Company Debts|Debts to Book Capitalization Ratio Procaps Group SA|PROC - Company Long-Term Debt|Short-Term Debt Volume Procaps|Intermediate Coverage Ratio procapsgroup.com
- earnings and valuation multiples information:
PROC - Net Profit|Projected Net Profit Procaps Group S.A.|PROC - Price to Earnings Ratio|Future Price to Earnings Multiple Procaps Group|PROC - Price/Earnings to Growth Ratio|Company Value to EBITDA Procaps Group SA|PROC - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Procaps|PROC - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months procapsgroup.com|PROC - Net earnings per share growth this year|Expected earnings per share trend next year Procaps Group S.A.
- total revenue and sales volume data:
PROC - Company Revenue|Company Future Sales procapsgroup.com|PROC - Market Cap to Revenue|Market Cap to Expected Sales Ratio Procaps Group SA
Fundamental company analysis:procapsgroup.com - PROC
Original product of Procaps Group SA

Stable demand for Procaps Group S.A. softgels creates a foundation for valuing the business via P/S, which measures the company's market value relative to its annual revenue. By analyzing the price-to-sales ratio, an investor can determine whether they are overpaying for current sales amid management risks and Latin American currency volatility.

Competitors of Procaps Group S.A.

HLN (haleon.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue KVUE|VRNA (Verona Pharma PLC) - Price-to-Sales Ratio|MENS - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio LGND (Ligand Corp)|Amneal Pharmaceuticals (AMRX) - Price-to-Revenue Ratio|Price to Sales perrigo.com (PRGO)|ALVO (Alvotech SA) - P/S Multiple|Market Cap to Revenue Liquidia Corp (LQDA)|P/S Multiple GLPG|P/S Multiple ANI Pharmaceuticals Corp (ANIP)|Price-to-Revenue Ratio MannKind Corporation MNKD|AMPH (amphastar.com) - Price-to-Sales Ratio|PCRX - Price-to-Revenue Ratio|Price-to-Revenue Coefficient ARS Pharmaceuticals Inc SPRY|TBPH (Theravance) - Market Cap to Revenue|Aquestive Corp - Market Capitalization-to-Revenue Ratio|SCPH (scPharmaceuticals, Inc.) - P/S Multiple|TECX - Price-to-Revenue Multiple|Price-to-Revenue Ratio Tonix Pharmaceuticals Holding Corp. (TNXP)|SXTC (sxtchina.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Eupraxia Pharmaceuticals Inc. EPRX|BioHarvest Sciences Inc (BHST) - Price to Sales|EXOZ: Market Cap to Revenue|ORMP - P/S Multiple|enterabio.com (ENTX) - Price-to-Revenue Ratio|Price-to-Sales Ratio HYFT (MindWalk Holdings, Inc.)|Market Cap to Revenue ABVC|CPIX: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Quantum BioPharma Ltd (QNTM)|Price-to-Revenue Coefficient fibrogen.com|Telomir Pharmaceuticals, Inc. - Market Cap to Revenue|Price-to-Revenue Coefficient Rani Therapeutics Holdings (RANI)|Synergy CHC Corporation - P/S Multiple|RLYB - P/S Multiple|LEXX (lexariabioscience.com) - Market Cap to Revenue|PULM - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Pheton Holdings Limited|Aptorum - Price-to-Sales Ratio|Price-to-Revenue Ratio Lyra Therapeutics, Inc (LYRA)|IBO (Impact BioMedical, Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio TNF Pharmaceuticals, Inc. TNFA|cbdMD Inc. (YCBD) - Price to Sales|PainReform - P/S Multiple|Altamira Therapeutics (CYTO) - Market Cap to Revenue|Lipella (LIPO) - Price-to-Revenue Ratio|Price-to-Sales Ratio OPTN (OptiNose Corp)|PIRS (Pieris Pharmaceuticals) - P/S Multiple|PTPI: Market Capitalization-to-Revenue Ratio|P/S Multiple QLI|P/S Multiple Acelyrin Inc. (SLRN)|Price-to-Revenue Ratio TFF Pharma TFFP